The Scientist

» biotech

Most Recent

image: Incentivizing Breakthroughs

Incentivizing Breakthroughs

By | December 1, 2014

With scientific funding on shaky ground, big-dollar competitions offer a new way for life-science innovators to bring their ideas to fruition.

1 Comment

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

image: The Promise of Nanomedicine

The Promise of Nanomedicine

By | April 8, 2014

At AACR, scientists discuss the growing interest in nanotechnology and how it can be used to study, diagnose, and treat cancer.

0 Comments

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

1 Comment

image: New Year’s Biotech IPO Boom?

New Year’s Biotech IPO Boom?

By | February 3, 2014

January was a profitable month for biotech companies going public, Burrill & Company says.

5 Comments

image: Penetrating the Brain

Penetrating the Brain

By | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.

3 Comments

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.

0 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.

0 Comments

Popular Now

  1. NYU Halts Studies, Suspends Investigator
    The Nutshell NYU Halts Studies, Suspends Investigator

    Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

  2. Exercise-Induced Muscle Factor Promotes Memory
  3. The Meaning of Pupil Dilation
    Daily News The Meaning of Pupil Dilation

    Scientists are using pupil measurements to study a wide range of psychological processes and to get a glimpse into the mind.

  4. Brexit’s Effects on Science